Mantis Biotech

-84%

est. 2Y upside i

HealthcareSeed

We are building a unified biomedical device testing and regulatory platform that connects every stage of product development from CAD design through simulation, bench testing, and verification to FDA Q-Submissions.

Rank

#361

Sector

Biotech Software / Healthtech

Est. Liquidity

~6Y

Data Quality

Data: Medium

Mantis Biotech presents a strong upside opportunity due to its innovative platform in a high-growth market, but this is tempered by its very early stage and the inherent risks of venture-backed startups.

Last updated: February 24, 2026

Bull (30%)+400%

Mantis Biotech achieves strong market adoption, expands its human digital twin platform into new high-value applications, and secures significant follow-on funding at increasing valuations.

Base (35%)+100%

Mantis Biotech establishes a solid customer base, demonstrates product-market fit, and raises a successful Series A or B round, leading to a moderate valuation increase.

Bear (35%)-80%

Mantis Biotech faces intense competition, struggles with regulatory hurdles, or fails to secure sufficient follow-on funding, leading to a down round or acquisition at a significantly reduced valuation.

Est. time to liquidity~6.0 years

Preference Stack Risk

high

With $7M in total funding against an estimated $30M current valuation, investors hold approximately 23.3% in liquidation preferences. In an exit at or below this valuation, common stock holders would only see returns after the initial $7M is covered.

Dilution Risk

high

As a very early-stage company (Seed round), Mantis Biotech will require several more funding rounds to scale, leading to significant future dilution for current equity holders.

Secondary Liquidity

none

Given its recent founding and seed stage, there is currently no active secondary market for Mantis Biotech's equity, limiting early liquidity options.

Community

Valuation Sentiment

Our model estimates -84% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.